Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 1.18B P/E - EPS this Y 16.00% Ern Qtrly Grth -
Income -192.65M Forward P/E -4.99 EPS next Y -12.60% 50D Avg Chg 3.00%
Sales 20.65M PEG - EPS past 5Y - 200D Avg Chg -6.00%
Dividend N/A Price/Book 2.32 EPS next 5Y - 52W High Chg -56.00%
Recommedations 1.80 Quick Ratio 14.34 Shares Outstanding 84.62M 52W Low Chg 47.00%
Insider Own 1.78% ROA -21.51% Shares Float 62.40M Beta 1.84
Inst Own 91.56% ROE -38.10% Shares Shorted/Prior 15.87M/16.25M Price 19.12
Gross Margin - Profit Margin - Avg. Volume 604,911 Target Price 25.13
Oper. Margin -879.24% Earnings Date - Volume 479,433 Change -1.54%
About Verve Therapeutics, Inc.

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Verve Therapeutics, Inc. News
11/06/24 Verve Therapeutics Third Quarter 2024 Earnings: Beats Expectations
11/05/24 Verve Therapeutics (VERV) Reports Q3 Loss, Tops Revenue Estimates
11/05/24 Verve Therapeutics: Q3 Earnings Snapshot
11/05/24 Verve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2024 Financial Results
11/01/24 Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
10/16/24 State Street Corp's Strategic Acquisition in Verve Therapeutics
10/03/24 Is Verve Therapeutics, Inc. (VERV) the Best NASDAQ Stock Under $5?
09/20/24 Jim Cramer on Vertiv Holdings (VRT): β€˜I Think It’s A Winner’
09/12/24 Millennium Management LLC's Strategic Acquisition in Verve Therapeutics Inc
09/08/24 Verve Therapeutics, Inc. (VERV): Among the Worst ARK Stocks According to Short Sellers
08/08/24 Verve Therapeutics (VERV) Reports Q2 Loss, Lags Revenue Estimates
08/08/24 Verve Therapeutics: Q2 Earnings Snapshot
08/08/24 Verve Therapeutics Announces Pipeline Progress and Reports Second Quarter 2024 Financial Results
08/01/24 We're Not Very Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Rate
07/08/24 Why Is Verve Therapeutics, Inc. (VERV) the Most Shorted Stock Loved by Analysts Now?
06/28/24 Verve Therapeutics Announces Appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its Board of Directors
06:46 AM One Verve Therapeutics Insider Raised Stake By 29% In Previous Year
05/31/24 Verve Therapeutics Announces Leadership Update
05/30/24 Verve Therapeutics to Participate in Upcoming Investor Conferences
05/17/24 Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for May 2024
VERV Chatroom

User Image zxxz Posted - 4 hours ago

$VERV

User Image RaKa82 Posted - 1 day ago

$VERV verve-102 is effectively derisked from a safety perspective because the lnp has been tested in over 100 patients. Plus, the safety issues in 102 - had there been any - would have already been reported as the lab abnormalities appear early on during the acute stage. Verv-101 Efficacy will be repeated in 102 and that efficacy is durable; lowered cholesterol levels remains in patients studied in 101. With $540M in cash and with partners like Lilly and Vertex, this stock is way undervalued.

User Image zxxz Posted - 2 days ago

$VERV

User Image RaKa82 Posted - 2 days ago

$VERV still absurdly oversold

User Image GSP Posted - 2 days ago

$HALO $SGMO $VERV $RGTI $SYM

User Image PaidPumper420 Posted - 2 days ago

$VERV Gurl SHUT UP and take my money

User Image McLovin13 Posted - 2 days ago

$VERV πŸ‘€

User Image GSP Posted - 2 days ago

The last 5 stocks in my video for November 19th: $HALO $VERV $SGMO $RGTI $SYM Watch here: https://greatstockpix.com/november-19th-day-trading-watch-list/ .

User Image juzbeachy Posted - 2 days ago

$VERV In for a swing. Mid-$4’s is too tempting. I have VERV in my IRA and it seems everytime it gets down to these levels it is good for a bounce. Of course in my IRA it means it’s basically gone nowhere.

User Image zxxz Posted - 2 days ago

$VERV

User Image RaKa82 Posted - 2 days ago

$VERV HEART-2 trial patients are in less severe state of disease and are scanned to exclude with blocked arteries. This will lead to good safety data in addition to excellent efficacy data

User Image RaKa82 Posted - 2 days ago

$VERV trading $150M under cash. Way oversold

User Image Mnpois Posted - 4 days ago

$VERV turn the stock into a crypto and there will be 10x more investors and no one has to pay capital gains tax

User Image PickemLowSellHigh Posted - 4 days ago

@aecids This is Scam St. just an excuse to trigger a selloff. It took me a few days to many to see the correlation until they actually announced RFK. After that I adding to my other position $IOVA and rebought $VERV yesterday just before close. Good chance he doesn't even get through the senate. they are already luke warm at best with his nomination.

User Image McLovin13 Posted - 6 days ago

$VERV just added back 2000 shares. πŸ‘πŸΌ

User Image DNAedit Posted - 6 days ago

$VERV is Base editing toast? $Beam and Verve are dropping big.

User Image zxxz Posted - 6 days ago

$VERV casual 20% drop in 3 trading sessions beautiful

User Image abdullahyim Posted - 1 week ago

$VERV? care to explain?

User Image Andysss Posted - 1 week ago

$VERV 12% in PM. It’s always a sign of β€œsell”. Funny how some are trying to manipulate it. Ends down 4%

User Image PaidPumper420 Posted - 1 week ago

$VERV πŸ‘€πŸ‘€πŸ‘€πŸ‘€

User Image BarneyR Posted - 1 week ago

$CRSP $BEAM $NTLA $CRBU $VERV Been waiting for interest rates to come down. The market started to reward our patience with the promise of lower interest rates. Hold on, Barrons and other outlets were called to sound the alarm about Trump's plans and how it'll slow down Fed actions, make them think twice. Thanks Donny, we can see what a great affect you're going to have on the economy. Let's make sure you talk more about deporting our labor workforce, implementing cross the board tariffs and spiking the debt ceiling with corporate tax cuts. Those who voted you in will be the first and most affected. Hard lessons on the way. Look at what happened to the market today, and all they said was how Trump's plans might affect the fed. No one mentioned recession. There's a long way to fall if markets get jittery.

User Image anachartanalyst Posted - 2 weeks ago

$VERV https://anachart.com/wp-content/uploads/ana_temp/1730912546_soc-img.jpg

User Image Zit1343 Posted - 2 weeks ago

$VERV 🚨 Follow me for more Alerts 🚨 & Gain πŸ’°πŸ’΅πŸ’²

User Image jbreaux123 Posted - 2 weeks ago

$VERV looks like a good buy

User Image Vitaliy11 Posted - 2 weeks ago

$VERV had a friend suggest this to me at 5$. Wish I bought! Good luck to Those that did! His firm suggested this is headed to 15$

User Image roblee1003 Posted - 2 weeks ago

$VERV still holding 4500 shares strong

User Image briefingcom Posted - 2 weeks ago

$VERV: Verve Therapeutics beats by $0.09, beats on revs https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20241105070730VERV&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

User Image Estimize Posted - 2 weeks ago

$VERV reported - EPS and - revenue for Q3. http://www.estimize.com/intro/verv?chart=historical&metric_name=eps&utm_content=VERV&utm_medium=

User Image Andysss Posted - 2 weeks ago

$VERV This comeback is going to be epic

User Image Thestocktraderhubzee Posted - 2 weeks ago

$VERV Verve Therapeutics Q3 2024 GAAP EPS $(0.59) Beats $(0.69) Estimate, Sales $6.87M Beat $2.81M Estimate

Analyst Ratings
Canaccord Genuity Buy Aug 12, 24
HC Wainwright & Co. Buy Aug 12, 24
RBC Capital Outperform Aug 9, 24
HC Wainwright & Co. Buy May 9, 24
Stifel Buy Apr 3, 24
RBC Capital Outperform Feb 28, 24
Cantor Fitzgerald Neutral Sep 13, 23
Cantor Fitzgerald Neutral Aug 29, 23
Guggenheim Buy Aug 15, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Bellinger Andrew CSO & CMO CSO & CMO Dec 14 Option 2.87 36,000 103,320 42,629 12/16/22
Bellinger Andrew CSO & CMO CSO & CMO Dec 01 Sell 22.95 865 19,852 6,629 12/02/22
Yeshwant Krishna Director Director Nov 04 Sell 32 48,583 1,554,656 4,260,047 11/08/22
GV 2017 GP, L.L.C. Other Other Nov 04 Sell 32 97,166 3,109,312 4,260,047 11/08/22
GV 2017 GP, L.L.C. Other Other Nov 02 Sell 34.52 156,440 5,400,309 4,308,630 11/04/22
Yeshwant Krishna Director Director Oct 31 Sell 38.69 85,659 3,314,147 4,386,850 11/02/22
Ashe Andrew D. See Remarks See Remarks Aug 25 Option 1.91 95,787 182,953 266,509 08/29/22
Kathiresan Sekar Chief Executive Offi.. Chief Executive Officer Aug 10 Option 1.39 50,000 69,500 367,839 08/11/22
Kathiresan Sekar Chief Executive Offi.. Chief Executive Officer Aug 10 Sell 29.9 50,000 1,495,000 317,839 08/11/22
Bellinger Andrew CSO & CMO CSO & CMO Jul 20 Option 1.39 20,000 27,800 26,629 07/22/22
Bellinger Andrew CSO & CMO CSO & CMO Jul 20 Sell 34.9 20,000 698,000 6,629 07/22/22
Kathiresan Sekar Chief Executive Offi.. Chief Executive Officer Jul 19 Option 1.39 50,000 69,500 367,839 07/21/22
Kathiresan Sekar Chief Executive Offi.. Chief Executive Officer Jul 19 Sell 29.9 50,000 1,495,000 317,839 07/21/22
Bellinger Andrew CSO & CMO CSO & CMO Jul 13 Option 1.48 10,000 14,800 16,629 07/15/22
Bellinger Andrew CSO & CMO CSO & CMO Jul 13 Sell 24.9 10,000 249,000 6,629 07/15/22
FMR LLC 10% Owner 10% Owner Jul 12 Sell 21.01 163,000 3,424,630 570,729 07/14/22
Kathiresan Sekar Chief Executive Offi.. Chief Executive Officer Mar 18 Option 2.87 69,674 199,964 477,525 03/22/22
ADELMAN BURT A Director Director Mar 15 Buy 21.3838 4,000 85,535 8,700 03/17/22
FMR LLC 10% Owner 10% Owner Mar 09 Sell 29.01 3,971 115,199 825,723 03/11/22
FMR LLC 10% Owner 10% Owner Feb 09 Sell 29.46 13,190 388,577 829,694 02/11/22
FMR LLC 10% Owner 10% Owner Feb 01 Sell 29.04 35,574 1,033,069 842,884 02/03/22
FMR LLC 10% Owner 10% Owner Jan 26 Sell 30.41 158,836 4,830,203 878,458 01/28/22
Bellinger Andrew Chief Scientific Off.. Chief Scientific Officer Dec 22 Option 1.48 15,000 22,200 20,000 12/27/21
Bellinger Andrew Chief Scientific Off.. Chief Scientific Officer Dec 22 Sell 38.47 15,000 577,050 5,000 12/27/21
Kathiresan Sekar Chief Executive Offi.. Chief Executive Officer Dec 22 Option 1.39 114,000 158,460 463,536 12/27/21
Kathiresan Sekar Chief Executive Offi.. Chief Executive Officer Dec 22 Sell 38.89 114,000 4,433,460 406,536 12/27/21